The association between advanced glycation end products (AGEs) and ABC (hemoglobin A1C, blood pressure, and low-density lipoprotein cholesterol) control parameters among patients with type 2 diabetes mellitus

Mohaddeseh Rezaei1, Soghra Rabizadeh2, Maryam Mirahmad1, Minoo Sadat Hajmiri3, Manouchehr Nakhjavani2, Mahboobeh Hemmatabadi1,2* and Nooshin Shirzad1,2*

Abstract

Background: Diabetes-induced chronic hyperglycemia results in the formation and aggregation of advanced glycation end-products (AGEs), which are products of non-enzymatic glycosylation of lipids or proteins. The development of diabetic complications can be accelerated by AGEs. In the current study, we aimed to explore the relationship between AGEs levels and ABC goals of diabetes control (A: Hemoglobin A1C < 7.0%, B: Blood pressure < 140/90 mmHg, and C: low-density lipoprotein cholesterol [LDL] < 100 mg/dL).

Methods: In the current cross-sectional study, 293 patients with type 2 diabetes mellitus (T2D), were enrolled. Demographic and clinical characteristics of the individuals were collected. AGEs levels were measured using quantitative fluorescence spectroscopy. Finally, the association of AGEs levels with patients’ characteristics and ABC goals was assessed.

Results: Higher serum AGEs concentration was detected in older age, smoking patients and those with higher diastolic blood pressure, lower high-density lipoprotein (HDL) level, lower body mass index (BMI) and retinopathy. Moreover, the T2D patients who achieved higher numbers of ABC goals of diabetes were younger age (P-value = 0.003), with lower hemoglobin A1C (P-value = 0.001), fasting blood sugar (P-value = 0.002), diastolic blood pressure (P-value = 0.001), systolic blood pressure (P-value = 0.001), cholesterol (P-value = 0.001), LDL (P-value = 0.001), and AGEs (P-value = 0.023) levels. Diabetic patients with AGEs levels above 73.9% were about 2.2 times more likely to achieve none of ABC treatment goals (95% CI 1.107–3.616).

Conclusion: Our results revealed the relationship between AGEs and ABC goal achievement, and microvascular diabetic complications, and imply that AGEs measurement may be valuable in the monitoring of diabetic patients’ complications and treatment adjustment.
Background
According to the statistics from the International Diabetes Federation, the global population of people aged 20–79 years living with diabetes is estimated to be around 537 million cases. Furthermore, the number of adult diabetic individuals is projected to increase in the future decades as a result of industrialization, aging, and changes in physical activity and diet. By 2045, the total number of patients with diabetes is expected to reach about 783 million [1].

Approximately 90% of people with diabetes suffer from type 2 diabetes mellitus (T2D). The increasing number of undiagnosed patients and high prevalence of diabetes mellitus has led to a costly rise in the occurrence of diabetic complications. The complications of diabetes mellitus are categorized into microvascular complications such as retinopathy, nephropathy, and neuropathy, as well as macrovascular complications (e.g., cardiovascular disease [CVD]) [2].

Intensive control of blood glucose [3], Lipid profile [4], and blood pressure (BP) [5] can help to lower the risk of diabetic complications. Adults with diabetes should maintain defined ABC goals (A: hemoglobin A1C [HbA1C] < 7.0%, B: BP < 140/90 mmHg, and C: low-density lipoprotein cholesterol [LDL] < 100 mg/dL), according to American Diabetes Association guidelines [6].

Chronic hyperglycemia caused by diabetes results in the aggregation of non-enzymatically derived glycosylation products of lipids and proteins. Advanced glycation end-products (AGEs) contribute to the pathogenesis of chronic diabetic complications [7]. AGEs are comprised of a heterogeneous set of complex molecules that are produced by non-enzymatic reactions involving free amino groups on nucleic acids, proteins, or lipids and carbonyl groups of reducing sugars. In individuals with diabetes, the production and accumulation of AGEs, which are natural aging processes driven by hyperglycemia, occurs at a faster rate [8].

RAGE is produced as a result of intrinsic cellular signaling that is induced by AGEs. AGEs and their receptors (RAGE) are thought to be crucial components of the inflammatory processes that might lead to diabetes and its complications [9]. Furthermore, early hyperglycemia is thought to cause a proportionate rise in AGEs production and oxidative stress. In hyperglycemic conditions, proteins related to mitochondrial respiratory chain proteins come to be more glycated, and mitochondrial deoxyribonucleic acid (DNA) gets damaged, leading to a self-perpetuating loop of oxidative stress and AGE construction [10].

Several preclinical and clinical investigations revealed that interventions for AGEs could help to reduce and prevent diabetic vascular complications [11]. Based on the pivotal role of AGEs in establishing oxidative stress and vascular disease, in this cross-sectional study we planned to investigate the association between AGEs levels and ABC goals of diabetes control. This may enhance the monitoring of diabetic patients and selection of more effective therapeutic approaches.

Methods
Study design
This cross-sectional study was prospectively conducted from January 2019 to December 2020. The study was carried out in the diabetes clinic of the Vali-Asr Hospital, affiliated with the Tehran University of Medical Science. The sample size was estimated by a statistic advisor by the following formula and considering a 5% margin of error, level of confidence of 95% (z = 1.96), d (precision) of 0.06 and P (expected prevalence of 0.5) which resulted in a sample size of 267. Considering the probable dropout of 20%, 320 participants were proposed of which 23 patients declined to enroll in the study.

\[ N = \left( \frac{Z_1 - \alpha/2}{\sigma} \right)^2 \times \frac{P(1 - P)}{d^2} \]

Accordingly, a final sample size of 293 patients was included. Included patients were previously diagnosed with T2D, who were referred to the outpatient diabetes clinic for routine follow-up.

Inclusion and exclusion criteria
All of the following inclusion and exclusion criteria were met by patients who enrolled in the research.

Inclusion criteria were defined as patients who:

1. Diagnosed with T2D for at least one year according to American diabetes association criteria [12]; and
2. Had complete demographic and previous clinical data in medical records.

Exclusion criteria were defined as patients who:

1. Were not satisfied to participate in this research;
2. Had known history of acute and/or chronic infection, chronic diseases, gestational diabetes mellitus, psychiatric illness, malignancies, pregnancy, end-stage renal disease, or blood transfusion in the last 3 months; and
3. Current use of cytotoxic, glucocorticoids, or immunosuppressive agents

Data collection methods
A specialized endocrinologist visited T2D patients and trained investigators carried out an interview based on a standard questionnaire. Following demographic and clinical characteristics were recorded; sex, age, duration of diabetes, smoking status, alcohol intake, history of any diseases, anti-diabetic agent use, and any medication use.

Blood pressure, height, and weight were measured from all study participants. The 24-h urine samples were collected by patients to measure proteinuria. Fasting blood samples (10 cc) were taken from all individuals and were stored at −80 °C until the testing time. Subsequently, fasting blood sugar (FBS), lipid profile, HbA1C level, creatinine, and AGEs levels were measured. Serum lipid concentrations (cholesterol, high-density lipoprotein [HDL], LDL, and triglycerides) were measured using direct enzymatic methods (Parsazmun, Karaj, Iran). FBS was determined using enzymatic calorimetric methods by the glucose oxidase test. HbA1C level was determined using high-performance liquid chromatography (A1C, DS5 Pink kit; Drew, Marseille, France). Urinary albumin concentrations were measured by an immunoturbidimetric commercial kit (Randox, Antrim, UK). AGEs levels were measured by the spectrophotometry method (FLUO star OPTIMA, BMG, Germany) described by Kalousová et al. The intra- and inter-assay analytical coefficient of variation were determined as 5.1% and 7.9%, respectively. [13]. The blood samples obtained from the patients were diluted to the ratio of 1 to 50 in peripheral blood smear pH 7.4. Fluorescence intensity was assessed at 350 nm excitation and 440 nm emission and indicated as the proportion of fluorescence emission expressed as percentages.

Statistical analyses
To evaluate the normality of the data, the Kolmogorov–Smirnov test was used. Continuous data are shown as mean ± standard deviation (SD), and categorical variables are expressed as percentages. The Chi-square test was employed to investigate the association between categorical variables. To assess the mean differences between the two groups, the independent t-test was performed. Additionally, one-way ANOVA was applied to assess if there is any significant difference between means of more than two groups. AGEs concentration was analyzed to build the Receiver Operating Characteristics (ROC) curve and to define the optimum cut-off value, sensitivity, and specificity of serum AGEs to predict ABC diabetic goal achievement. Multivariable logistic regression examined the adjusted odds ratio of AGEs levels to predict ABC goal achievement of diabetes. All statistical analyses were conducted with IBM SPSS software, version 22.0 (SPSS Inc., Chicago, Illinois, USA), with a two-tailed P < 0.05 regarded as statistically significant.

Ethics
The Research Ethics Committee of The Tehran University of Medical Sciences authorized the study protocol (ethical approval code: IR.TUMS.IKHC.1399.265). After approval, the study was initiated. Participants had been explained about the project and everyone had given written informed consent to participate. The participants’ identities and records are kept privately. The patient’s treatment and pharmacological intervention would not change due to this research. This research has been conducted in agreement with the Declaration of Helsinki (2000) of the World Medical Association [14].

Definitions
Treatment goals
According to the 2015 American diabetes association guidelines, the ABC goals for diabetes treatment were defined as HbA1c < 7.0%, LDL < 100 mg/dL, and BP < 140/90 mmHg (6).

Smoking cigarettes
Study participants who had the habit of smoking during the study period. More than one cigarette every day for at least six months was considered smoking [15].

Fasting blood glucose
FBS ≥ 126 and FBS < 126 were defined as poor glycemic control and controlled FBS levels, respectively.

Blood pressure
Hypertension was regarded as taking antihypertensive drugs or systolic blood pressure (SBP) ≥ 140 mmHg, and/
or diastolic blood pressure (DBP) ≥ 90 mmHg quantified by automatic BP monitors in a sitting position [16].

**Different treatments for diabetes**
(1) oral use of anti-diabetic drugs, (2) Insulin, and (3) Both oral and insulin.

**HbA1c**
we defined HbA1c ≥ 9% as poor glycemic control, HbA1c 7–9% as sub-optimal and HbA1c < 7% as optimal glycemic control.

**Triglycerides**
amounts less than 150 mg/dL were considered normal and amounts equal to or more than that were defined as high triglycerides.

**LDL and HDL and cholesterol**
Amounts lower than 100 mg/dL for LDL and higher or equal to 40 mg/dL in males and more than 50 mg/dL in females for HDL and below 200 mg/dL for cholesterol were considered optimal control.

**Anthropometric measurements**
Using stretch-resistant tape, the midpoint between the bottom border of the last palpable rib and the superior margin of the iliac crest, was used to measure the circumference of the waist; the waist circumference greater than 88 cm for women and 102 cm for men was then regarded as central obesity.

**BMI (body mass index)**
Based on the definition of the World Health Organization, BMI is defined as dividing a person's weight (Kg) divided by height in meters squared (Kg/m²). In the categorization, below 25 is the optimal number, over 25 is considered overweight, and over 30 is obese.

**Microalbuminuria**
It was defined as between 30 and 300 mg/day of urine albumin excretion.

**Results**
This research involved 293 participants with T2D. In total, about 60.4% (n = 177) were females and the others were male 39.6% (n = 116). As shown in Table 1, the majority of adults were aged 40–60 years old (60.8%), and 31.7% were equal to or above 60 years old. The average study population was 55.09 years old. The mean duration of diabetes among all patients was 7.65 years. Patients were mostly using just oral drugs to control their diabetes (61.4%). Besides, about 24.6% were on oral anti-diabetes drugs plus insulin at the same time. The prevalence of smoking was about 4.1%. In terms of BMI, 39.6% were normal weight and 38.6% were overweight, and the mean BMI was 27.37 kg/m².

The average FBS was 186.05 mg/dL. The majority of patients (91.1%) had high FBS (≥ 126 mg/dL). Their mean HbA1C level was 8.18%. Notably, about 43% and 27.6% had HbA1C between 7–9% and ≥ 9%, respectively. The mean (±SD) of SBP and DBP were 125 ± 19.7 mmHg and 77.8 ± 10 mmHg, respectively. The mean (±SD) of HDL, LDL, and TG were 45 ± 9.6 mg/dL, 111 ± 33 mg/dL, and 166.8 ± 80 mg/dL, respectively. The level of TC was 190 ± 42 mg/dL. The mean AGEs level was 74.91 ± 12.78%.

Furthermore, we investigated if there is any significant association between AGEs levels and other variables. The findings revealed a strong correlation between AGE levels and BMI (P-value 0.016), DBP (P-value = 0.045), HDL (P-value = 0.042), and cigarette smoking (P-value = 0.004). Additionally, the AGEs level was significantly associated with the presence of microvascular diseases (P-value = 0.001) and retinopathy (P-value = 0.001). No association between the AGEs levels and the presence of neuropathy, CVD, and microalbuminuria was found (Table 2).

Patients were categorized into four groups based on ABC goal achievement. A total of 67 patients (22.9%) had not achieved any of the ABC goals. More significantly, 108 people (36.9%) had achieved only one of the ABC goals. Ninety-three patients (31.7%) had reached a couple of goals and only 25 patients (8.5%) had successfully achieved all three ABC goals.

As shown in Fig. 1a, a large percentage of patients (35.8%) whose AGEs were in the highest quartile, had not reached any of the ABC goals. Patients who had reached a couple of ABC goals (Fig. 1c), were mostly (34.4%) placed in the first quartile of AGEs levels, which means they had a lower rate of AGE among all diabetic patients. Moreover, based on Fig. 1d, a much lower percentage (16%) of those patients who had reached all three goals of ABC, was placed in the fourth (highest) quartile of the AGEs level.

As a result, we hypothesized that the AGEs level may be a predictive factor for achieving the ABC goals. AUC-ROC analysis results indicate an AUC of 0.62 (95% CI 0.538–0.692), a sensitivity of 67%, and a specificity of 53%. The measured cut-off was 73.9 (Fig. 2).
Table 1  Baseline characteristics of the patients

| Variable                  | Frequency (%) | Mean ± SD     | AGEs (Mean ± SD) | P-value |
|---------------------------|---------------|---------------|------------------|---------|
| Age group (years)         |               |               |                  |         |
| ≥ 40                      | 22 (7.5%)     | 55.09 ± 10.00 | 71.66 ± 12.23    | 0.428   |
| 40–60                     | 178 (60.8%)   | 75.40 ± 11.73 |                  |         |
| ≤ 60                      | 93 (31.7%)    | 74.71 ± 14.70 |                  |         |
| BMI (kg/m²)               |               |               |                  |         |
| < 25                      | 64 (21.8%)    | 27.38 ± 3.95  | 77.79 ± 11.89    | 0.016*  |
| 25–30                     | 116 (39.6%)   | 75.78 ± 12.45 |                  |         |
| ≥ 30                      | 113 (38.6%)   | 72.36 ± 13.22 |                  |         |
| Central obesity           |               |               |                  |         |
| No                        | 131 (44.7)    | NA            | 75.61 ± 12.31    | 0.725   |
| Yes                       | 162 (55.3)    | 75.12 ± 13.18 |                  |         |
| Smoking                   |               |               |                  |         |
| No                        | 281 (95.9%)   | NA            | 74.47 ± 12.74    | 0.004*  |
| Yes                       | 12 (4.1%)     | 85.14 ± 9.23  |                  |         |
| FBS (mg/dL)               |               |               |                  |         |
| < 126                     | 26 (8.9%)     | 186.05 ± 61.19| 71.88 ± 13.5     | 0.207   |
| ≥ 126                     | 267 (91.1%)   | 75.19 ± 12.6  |                  |         |
| HbA1C (%)                 |               |               |                  |         |
| < 7%                      | 86 (29.4%)    | 8.18 ± 1.87   | 73.55 ± 12       | 0.323   |
| 7–9%                      | 126 (43%)     | 74.78 ± 13.4  |                  |         |
| ≥ 9%                      | 81 (27.6%)    | 76.52 ± 12.4  |                  |         |
| SBP (mmHg)                |               |               |                  |         |
| < 140                     | 219 (74.7%)   | 125.73 ± 19.79| 74.20 ± 12.3     | 0.107   |
| ≥ 140                     | 74 (25.3%)    | 76.97 ± 13.8  |                  |         |
| DBP (mmHg)                |               |               |                  |         |
| < 90                      | 240 (81.9%)   | 77.82 ± 10.56 | 74.10 ± 12.2     | 0.045*  |
| ≥ 90                      | 53 (18.1%)    | 78.52 ± 14.6  |                  |         |
| Therapeutic agent         |               |               |                  |         |
| OHA                       | 180 (61.4%)   | NA            | 74.60 ± 12.18    | 0.326   |
| Insulin                   | 41 (14%)      | 76.21 ± 14.44 |                  |         |
| Insulin + OHA             | 72 (24.6%)    | 74.93 ± 13.39 |                  |         |
| Cholesterol (mg/dL)       |               |               |                  |         |
| < 200                     | 177 (60.4%)   | 190.42 ± 42.25| 74.38 ± 12.8     | 0.389   |
| ≥ 200                     | 116 (39.6%)   | 75.70 ± 12.6  |                  |         |
| Triglycerides (mg/dL)     |               |               |                  |         |
| < 150                     | 149 (50.9%)   | 166.84 ± 80.36| 75.04 ± 12.5     | 0.849   |
| ≥ 150                     | 144 (49.1%)   | 75.75 ± 13.0  |                  |         |
| LDL (mg/dL)               |               |               |                  |         |
| < 100                     | 114 (38.9%)   | 111.13 ± 33.44| 74.13 ± 13.0     | 0.411   |
| ≥ 100                     | 179 (61.1%)   | 75.39 ± 12.5  |                  |         |
| HDL (mg/dL)               |               |               |                  |         |
| < 40                      | 82 (28%)      | 45.38 ± 9.61  | 77.34 ± 13.3     | 0.042*  |
| ≥ 40                      | 211 (72%)     | 73.95 ± 12.4  |                  |         |

AGEs, advanced glycation end-products; BMI, Body mass index; FBS, Fasting blood sugar; HbA1C, hemoglobin A1c; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; OHA, Oral hypoglycemic agents; LDL, low-density lipoprotein; HDL, high-density lipoprotein

*P < 0.05
Afterward, we investigated the association between ABC goal achievement of diabetes, and clinical and demographic characteristics of patients (Table 3). The findings revealed that there is a correlation between ABC goal achievement and the patient’s age (P-value = 0.003), FBS (P-value = 0.002), and total cholesterol (P-value = 0.001) in addition to factors related to ABC goal achievements (HbA1C [P-value = 0.001], DBP [P-value = 0.001], SBP [P-value = 0.001], LDL [P-value = 0.001]) in multiple variable logistic regression analysis.

AGEs level was an independent predictor of no achievement of all three ABC goals after adjustment for age, sex, BMI, duration of diabetes, cardiovascular disease, and microvascular complications (OR: 2.29, 95% CI 1.02–5.18, P value:0.04).

**Discussion**

In the current cross-sectional study, we explored the possible relationship of AGEs levels with clinical characteristics, macro- and microvascular complications of diabetic patients, and ABC goal achievement.

In the current study, it has been specified that smoker patients and those with higher DBP and lower HDL have statistically higher levels of serum AGEs concentration. Similarly, in the study by Indyk et al., there was a negative correlation between HDL level and concentration of melibiose-derived glycation product (MAGE) (r = −0.4220, P-value = 0.0093), which is a new class of AGEs, while there was no significant relationship among AGEs and LDL or total cholesterol [17]. Chang et al. introduced AGEs levels as a marker for poor lipid profile and atherosclerosis in diabetic individuals, with an even stronger association than FBS or HBA1c levels [18]. Previously, it has been shown that compared to non-smokers, AGEs accumulate in the tissues of smokers at higher levels, irrespective of diabetes [19]. Reactive glycation products present in cigarette smoke have been shown to promote AGE buildup in smokers’ blood and tissues [20]. Another study indicated that AGEs were related to the pathophysiology of obesity [21]. We found a significant relationship between BMI and AGEs levels (P-value = 0.016). Remarkably, normal weight T2D patients (BMI < 25 kg/m²), had higher mean serum AGEs levels compared to overweight and obese T2D patients. Earlier studies reported a similar association in both diabetic and non-diabetic individuals [21, 22]. In the same way, Gaens et al. reported that waist circumference is negatively associated with plasma concentration of CML (Nε-carboxymethyl lysine), which is a circulating AGEs (standardized regression coefficient [β] = −0.357 [95% CI −0.414; −0.301], P < 0.001) [23]. At first glance, it seems paradoxical but could be rationalized by a concept that proposes decreased plasma AGEs levels might be attributed to AGEs being predominantly deposited in adipose tissue [24].

Because of their long residence duration in the human body, AGEs are currently thought to be a possible diagnostic marker. Monitoring of AGEs levels may enable the determination of disease progression, and therapeutic efficacy [17].

We indicated a relationship between elevated AGEs serum concentration and the occurrence of any microvascular complication (P-value ≤ 0.001), particularly retinopathy (P-value ≤ 0.001). Although in the cases of neuropathy and nephropathy, the AGEs levels were higher, the relationship was not statistically significant. This finding is different from previous studies which have demonstrated that AGEs or their receptor (RAGE) levels were significantly associated with diabetic neuropathy [25] and nephropathy [26, 27].

AGEs contribute to diabetes mellitus macro- and microvascular complications through adduct formation. Adducts form in basement membranes and cause changes in extracellular matrix proteins like elastin and collagen [28]. Moreover, it is suggested that AGEs, through interaction with RAGE, may result in the

| Table 2 Association between AGEs level and diabetic complications |
|------------------------|-----------------|-----------------|
| Variable               | N (%)           | AGEs level (%)  | P-value    |
| Microvascular complications |                |                |            |
| No                     | 174 (59.4)      | 70.41±11.70    | <0.001*    |
| Yes                    | 119 (40.6)      | 81.48±11.41    |            |
| Retinopathy            |                |                |            |
| No                     | 230 (78.5)      | 71.98±11.46    | <0.001*    |
| Yes                    | 63 (21.5)       | 85.60±11.66    |            |
| Neuropathy             |                |                |            |
| No                     | 196 (66.9)      | 75.20±12.7     | 0.540      |
| Yes                    | 96 (33.8)       | 74.22±13.1     |            |
| Microalbuminuria       |                |                |            |
| No                     | 209 (71.3)      | 74.62±11.5     | 0.720      |
| Yes                    | 81 (27.6)       | 75.30±15.5     |            |
| CVD                    |                |                |            |
| No                     | 236 (80.5)      | 75.25±12.6     | 0.421      |
| Yes                    | 57 (19.5)       | 73.48±15.4     |            |

AGEs, advanced glycation end-products; CVD, cardiovascular disease

*P < 0.05
inflammatory process, oxidative stress, as well as development of clots and calcification in the arteries. As a result, AGES are linked to blood vessel aging and damage. These findings imply that both AGES and RAGEs are potential therapeutic targets to avoid diabetes-related vascular complications [17, 29, 30].

The possible role of AGES in diabetic retinopathy is initiated by AGES binding to RAGE that triggers intracellular signaling cascades. Pro-inflammatory cytokines may be produced as a result of this mechanism and proangiogenic mediators that cause inflammation, pericyte apoptosis, angiogenesis, endothelial dysfunction, and lastly, blood-retinal barrier breakdown. These events cause damage to vessels and neurons of the retina [31].

High AGES levels are also reported to be related to poor diabetes control in terms of HbA1C [32, 33], lipid profile [18, 34], and blood pressure [33]. The current study has revealed that achieving the ABC goal is statistically associated with AGES levels (P value = 0.023). It was also shown that diabetic patients with AGES levels above 73.9% were 2.2 times more likely to achieve none of ABC treatment goals (95% CI 1.107–3.616). The result remains significant after adjustment of possible confounders like age, sex, and BMI. In a prospective cohort study of 781 individuals, it was observed that individuals reported that the average level of AGES in normoglycemic individuals is about 246 µU/mL in baseline samples, while those with AGES concentration equal to or higher than 450 µU/mL
had about tenfold greater risk to develop T2D, 7 years later [35].

The basic limitation of the current investigation is the use of cross-sectional information, which prohibits us from establishing causal associations. Another limitation is that we did not investigate the role of antihypertensive and lipid-lowering drugs in the ABC treatment goals. It is worth mentioning that our proposed AGEs assay did not include measurement of melibiose-derived AGE (MAGE), which is produced from melibiose during in vitro glycation of proteins and protein-free amino acids in anhydrous conditions [36]. Furthermore, some factors like physical activity and diet are possible contributors to AGEs and diabetes complications, which have not been measured and adjusted [37]. Future multicenter research may address these limitations.

Conclusion

In conclusion, current research revealed the relationship between AGEs and ABC goal achievement, and microvascular diabetic complications. Higher levels of serum AGEs were detected in older age, smoking patients and those with higher DBP, lower HDL levels, lower BMI and retinopathy. Moreover, diabetic patients with high AGEs

Table 3 The association between ABC goal achievement of diabetes, and clinical and demographic characteristics of patients

| Variables            | Number of ABC goals achieved | P-value |
|----------------------|------------------------------|---------|
|                      | No  | One  | Two  | Three |         |
| Age (years)          |     |      |      |       |         |
|                      | 58.98 ± 9.3       | 54.39 ± 9.9       | 53.99 ± 9.7       | 52.44 ± 10.2       | 0.003*    |
| Sex                  |     |      |      |       |         |
| Female               | 19.2% | 36.7% | 33.3% | 10.7% | 0.148 |
| Male                 | 28.4% | 37.1% | 29.3% | 5.2%  |         |
| Duration of T2D (years) | 8.46 ± 5.9       | 6.93 ± 5.6       | 7.72 ± 6.4       | 6.12 ± 4.5       | 0.234 |
| FBS (mg/dL)          | 197.9 ± 63        | 194.5 ± 67        | 173.9 ± 55        | 156.8 ± 32        | 0.002*    |
| HbA1C (%)            | 8.8 ± 2.0         | 8.4 ± 1.3         | 7.7 ± 1.8         | 6.2 ± 0.5         | 0.001*    |
| SBP (mmHg)           | 133.94 ± 21.9     | 129.36 ± 20.6     | 119.26 ± 14.7     | 112.12 ± 10.5     | 0.001*    |
| DBP (mmHg)           | 80.79 ± 10.7      | 79.45 ± 10.4      | 74.94 ± 10.3      | 73.48 ± 7.1       | 0.001*    |
| Cholesterol (mg/dL)  | 210.26 ± 39       | 198.41 ± 43       | 175.65 ± 36       | 157.56 ± 27       | 0.001*    |
| Triglycerides (mg/dL)| 171.53 ± 72       | 168.60 ± 82       | 161.61 ± 79       | 166.04 ± 98       | 0.880 |
| LDL (mg/dL)          | 138.98 ± 25       | 112.64 ± 31       | 97.39 ± 29        | 81.13             | 0.001*    |
| HDL (mg/dL)          | 44.75 ± 9         | 45.39 ± 9         | 45.89 ± 10        | 45.08 ± 9         | 0.904 |
| BMI (kg/m²)          | 26.56 ± 3.6       | 27.37 ± 3.9       | 28.4 ± 4.0        | 27.24 ± 3.8       | 0.155 |
| AGEs (%)             | 78.42 ± 13.1      | 75.25 ± 12.9      | 72.17 ± 12.3      | 74.11 ± 10.4      | 0.023 |
| Albuminuria (mg/day) | 78.67 ± 15        | 74.86 ± 24        | 84.20 ± 28        | 78.38 ± 20        | 0.523 |
| Treatment            |     |      |      |       |         |
| OHA                  | 24.4% | 36.7% | 28.3% | 10.6% | 0.056  |
| Ins                  | 22%   | 51.2% | 26.8% | 0.0%  |         |
| OHA + Ins            | 19.4% | 29.2% | 43.1% | 8.3%  |         |

T2D, Type 2 diabetes mellitus; FBS, Fasting blood sugar; HbA1C, Hemoglobin A1c; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, Body mass index; AGEs, advanced glycation end-products; OHA, Oral hypoglycemic agents; Ins, Insulin

*P < 0.05
levels were more likely to fail to achieve ABC treatment goals.

Abbreviations
AGEs: Advanced glycation end products; ABC: Hemoglobin A1C, blood pressure, and low-density lipoprotein cholesterol; LDL: Lipoprotein cholesterol; T2D: Type 2 diabetes mellitus; BMI: Body mass index; CVD: Cardiovascular disease; BP: Blood pressure; HbA1C: Hemoglobin A1C; RAGE: Receptor for advanced glycation end product; DNA: Deoxyribonucleic acid; FBS: Fasting blood sugar; SD: Standard deviation; ROC: Receiver operating characteristics; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; HDL: High-density lipoprotein; OHA: Oral hypoglycemic agents; MAGE: Melibiose-derived AGE.

Acknowledgements
None.

Author contributions
MH and NS conceptualized the idea and designed the study; MR, MM, MSH: collected the data and performed the analysis; MN and SR interpret the results; MR, MM, SR, and MSH: wrote the draft of the manuscript; MN, NS, and MH: participated in supervision, writing, reviewing and editing. All authors revised the manuscript critically. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital). The study protocol was approved by the Research Ethics Committee of the Tehran University of Medical Sciences (ethical approval code: IR.TUMS.EMRC.Vali-Asr Hospital).

Consent for publication
Not applicable.

Competing interests
All authors declare no conflicts of interest.

Author details
1 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Endocrinology, Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. 3 Department of Endocrinology, Hamadan University of Medical Sciences, Hamadan, Iran.

Received: 17 June 2022 Accepted: 21 August 2022
Published online: 26 August 2022

References
1. Sun H, Saedee P, Karuranga S, Pinkerpank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;218:109119. https://doi.org/10.1016/j.diabres.2021.109119.
2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. https://doi.org/10.1038/nrendo.2017.151.
3. Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet. 1998;352(9131):837–53.
4. Collins R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.
5. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.
6. Grant R, Clark N, Desouza C, Funnell M, Goldfine A, Lafler L. Standards of medical care in diabetes. Diabetes Care. 2011;34(7):887.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–20.
8. Bierhaus A, Hofmann MA, Ziegler R, Navroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res. 1998;37(3):586–600.
9. Aasidipooya K, Uy EM. Advanced glycation end products (AGEs), receptor for AGEs, diabetes, and bone: review of the literature. J Endocr Soc. 2019;3(10):1799–818. https://doi.org/10.1210/endoj.2019-00160.
10. Testa R, Bonfigli AR, Prattichizzo F, La Sala L, De Nigris V, Ceriello A. The “metabolic memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients. 2017;9(5):437.
11. Rhee SY, Kim YS. The Role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018;42(3):188–95. https://doi.org/10.4093/dmj.2017.0105.
12. Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement_1):S13–28.
13. Kaloussová M, Škrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002;51(6):597–604.
14. World Medical A. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. World Bull Health Organ. 2001;79(4):373–4.
15. Zhang M, Liu S, Yang L, Jiang Y, Huang Z, Zhao Z, et al. Prevalence of smoking and knowledge about the hazards of smoking among 170 000 Chinese adults, 2013–2014. Nicotine Tob Res. 2019;21(12):1644–51.
16. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, et al. 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension guidelines sub-committee of the World Health Organization. Clin Exp Hypertens. 1999;21(56):1009–60.
17. Indyk D, Broncowicka-Szydlo A, Gamian A, Kuzan A. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. Sci Rep. 2021;11(1):13264. https://doi.org/10.1038/s41598-021-92630-0.
18. Chang JB, Chu NF, Syu JT, Hsieh AT, Hung YR. Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients. Lipsids Health Dis. 2011;10:228. https://doi.org/10.1186/1476-511x-10-228.
19. Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB, Bucala R. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med. 1998;4(9):594–601. https://doi.org/10.1007/BF03401759.
20. Rungratanawanich W, Qu Y, Wang X, Ersa MM, Song B-J. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. 2021;53(2):168–88. https://doi.org/10.1038/s41227-021-00561-7.
21. Ruiz HH, Ramasamy R, Schmidt AM. Advanced glycation end products: building on the concept of the “common soil” in metabolic disease. Endocrinology. 2020;161(1):bqz006. https://doi.org/10.1210/endorc/bqz006.
22. Szébeková K, Somoza V, Játúčková M, Heiland A, Podracká L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes. 2009;4(2):112–8. https://doi.org/10.1111/j.1677-5641.2009.00087.x.
23. Agnes KH, Ferreira I, Van de Warenburg MP, van Greevenbroek MM, Van Der Kallen CJ, Dekker JM, et al. Protein-bound plasma N-carboxymethyl lysine is inversely associated with central obesity and inflammation and significantly explain a part of the central obesity–related increase in inflammation: the Hoorn and CODAM studies. Antierioscler Thromb Vasc Biol. 2015;35(12):2707–13.
24. Semba RD, Arab L, Sun K, Nicklett EJ, Ferrucci L. Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr. 2011;141(9):1726–30. https://doi.org/10.3945/jn.111.143172.

25. El-Mesallamy HO, Hamdy NM, Ezzat OA, Reda AM. Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Invest Med. 2011;59(8):1233–8. https://doi.org/10.2130/jim.0b013e318231db64.

26. Gohda T, Tanimoto M, Moon JY, Gotoh T, Aoki T, Matsumoto M, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008;81(2):196–201. https://doi.org/10.1016/j.diabres.2008.04.013.

27. Kerkeni M, Saidi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidide as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res. 2013;10(3):239–45.

28. Singh R, Barden A, Mon T, Belin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–46.

29. Toprak C, Yigitaslan S. Alagebrum and complications of diabetes mellitus. Eurasian J Med. 2019;51(3):285–92. https://doi.org/10.5152/eurasiandmed.2019.18434.

30. Sengi D, Bouleston H, Campbell FM, Williams LM. The role of dietary advanced glycation end products in metabolic dysfunction. Mol Nutr Food Res. 2021;65(1):1900994.

31. Xu J, Chen LJ, Yu J, Wang HU, Zhang F, Liu Q, et al. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. Cell Physiol Biochem. 2018;48(2):705–17. https://doi.org/10.1159/000491897.

32. Turk Z, Mesić R, Benko B. Comparison of advanced glycation end-products on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control. Clin Chim Acta. 1998;277(2):159–70. https://doi.org/10.1016/s0009-8981(98)00128-4.

33. Zhang Y, Jiang T, Liu C, Hu H, Dai F, Xia L, et al. Effectiveness of early advanced glycation end product accumulation testing in the diagnosis of diabetes: a health risk factor analysis using the body mass index as a moderator. Front Endocrinol. 2022;12:766778. https://doi.org/10.3389/fendo.2021.766778.

34. Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care. 2003;26(9):2609–15. https://doi.org/10.2337/diacare.26.9.2609.

35. Jimenez IU, Diaz-Diaz E, Castro JS, Ramos JP, Leon MC, Alvarado Rios JA, et al. Circulating concentrations of advanced glycation end products, its association with the development of diabetes mellitus. Arch Med Res. 2017;48(4):360–9. https://doi.org/10.1016/j.arcmed.2017.07.001.

36. Gostomska-Pampuch K, Gamian A, Rawicz-Pruszyński K, Gęca K, Tkaczuk-Wach J, Jonik I, et al. Proteins in human body fluids contain in vivo antigen analog of the melibiose-derived glycation product: MAGE. Sci Rep. 2022;12(1):7520. https://doi.org/10.1038/s41598-022-11638-2.

37. Ying L, Shen Y, Zhang Y, Wang Y, Yin J, Yin J, et al. Advanced glycation end products via skin autofluorescence as potential marker of carotid atherosclerosis in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2021;31(12):3449–56. https://doi.org/10.1016/j.numecd.2021.09.005.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.